Upstream Bio, Inc. UPB
Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026
Upstream Bio, Inc. (UPB) is a healthcare company listed in the US with a market value of about $152M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$164M, a net margin of -5712.3%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -25%.
About Upstream Bio
Upstream Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. It was profitable in 0 of the last 3 years in our data. It spends 4793% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $3M | $3M | $2M | $2M |
| Net income | -$164M | -$143M | -$63M | -$21M |
| Free cash flow | -$168M | -$133M | -$60M | -$38M |
| EPS (diluted) | $-3.01 | $-2.66 | $-5.58 | $-12.95 |
| Net margin | -5712.3% | -5026.0% | -2650.0% | -862.9% |
| ROIC | — | -37.1% | -13.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Upstream Bio pay a dividend?
Not currently.
Is Upstream Bio a good stock to buy?
We do not give buy or sell advice. Upstream Bio scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.